Product Description: Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc[1].
Applications: COVID-19-anti-virus
Formula: N/A
References: [1]Michael Bauer, et al. Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study). Crit Care Explor. 2021 Nov 17;3(11):e0577.
CAS Number: 2250440-41-4
Molecular Weight: N/A
Compound Purity: 99.27
Research Area: Infection; Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Complement System;SARS-CoV
English
Deutsch
